Shandong Lukang Pharma updates share issuance application reply

Shandong Lukang Pharmaceutical (the "Company") has updated its reply to the Shanghai Stock Exchange's ("SSE") inquiry letter concerning its application to issue shares to specific targets. This update follows an initial response released on June 18, 2025, addressing questions raised by the SSE's review. The Company has further refined its answers and revised relevant application documents based on additional feedback from the SSE. While the share issuance is still subject to SSE review and approval from the China Securities Regulatory Commission ("CSRC"), its eventual approval and timeline remain uncertain. The Company commits to timely disclosure of further developments related to this matter.